MTX combination vs MTX monotherapy: ACR 50 response of DMARDs naive patients Number of responders
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
MTX combination vs MTX monotherapy ACR 50 response of DMARDs naive patients Number of responders · patients with Rheumatoid arthritis MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty). Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane Headline outcomes only | RR 1.76 [0.64, 4.85] | 2 studies · 127 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid… 2010 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.